RemeGen Co., Ltd. (SEHK: 9995)
Health Care · Biotechnology · CN
HK$70.40
-3.43% today · -23.6% 1Y
RemeGen Co., Ltd. (SEHK: 9995) operates in the Biotechnology industry within the Health Care sector. The company is valued at $7.56B and employs 3,145 people.
Over the last twelve months the share price has lost 23.6%, trading between 63.30 and 123.10.
Tweenvest scores RemeGen Co., Ltd. across four factors: quality 49/100, value 52/100. Its strongest factor is value.
9995 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $7.56B
- Revenue (TTM)
- $1.18B
- P/E
- 5.87
- EPS
- 10.39
- Dividend yield
- —
- Beta (5Y)
- 0.46
- 52-week high
- HK$123.10
- 52-week low
- HK$63.30
- Avg volume (3M)
- —
- Shares outstanding
- 559.97M
- Employees
- 3,145
- Next earnings
- —
About RemeGen Co., Ltd.
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People’s Republic of China.
- ISIN
- CNE1000048G6
- Founded
- 2008
- Listed since
- Nov 9, 2020
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Caris Life Sciences, Inc.NasdaqGS: CAI | $8.39B | $29.02 | -2.29% |
| Spyre Therapeutics, Inc.NasdaqGS: SYRE | $8.01B | $85.66 | -0.04% |
| TG Therapeutics, Inc.NasdaqCM: TGTX | $7.85B | $55.67 | +0.54% |
| ABIVAX Société AnonymeENXTPA: ABVX | $7.71B | €79.00 | +2.46% |
| Ionis Pharmaceuticals, Inc.NasdaqGS: IONS | $7.52B | $44.13 | -2.54% |
| Praxis Precision Medicines, Inc.NasdaqGS: PRAX | $7.26B | $254.06 | -2.23% |
| Alkermes plcNasdaqGS: ALKS | $6.81B | $40.38 | -0.57% |
| Biocytogen Pharmaceuticals (Beijing) Co., Ltd.SEHK: 2315 | $6.75B | HK$69.20 | +2.59% |
Figures last refreshed Oct 11, 2026.